Novo Nordisk Investors Face September 30, 2025 Deadline to File Lead Plaintiff Motion

Strategic Insights -

The deadline for investors who purchased Novo Nordisk A/S securities between May 7, 2025, and July 28, 2025, to file a lead plaintiff motion is approaching. The class action alleges that Novo Nordisk made false and/or misleading statements about its business, operations, and prospects during this period. The Company's stock price fell significantly on July 29, 2025, after it cut its fiscal year 2025 guidance. The lawsuit claims that Novo Nordisk failed to disclose material adverse facts about its business, including its inability to capitalize on the unmet patient population.

Key Takeaways:

  • Novo Nordisk investors who purchased securities between May 7, 2025, and July 28, 2025, have until September 30, 2025, to file a lead plaintiff motion.
  • The class action alleges that Novo Nordisk made false and/or misleading statements about its business, operations, and prospects during the class period.
  • The Company's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, following the announcement of reduced guidance.
  • The lawsuit claims that Novo Nordisk failed to disclose material adverse facts about its business, including its inability to capitalize on the unmet patient population for GLP-1 compounding.
  • The complaint alleges that the Company's positive statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
  • Investors who wish to pursue claims to recover their losses under the federal securities laws can contact Glancy Prongay & Murray LLP.
  • The deadline for appointment as lead plaintiff is September 30, 2025.
  • Interested parties can contact Charles Linehan, Esq., at Glancy Prongay & Murray LLP for more information.

Statistics:

  • The class period spans from May 7, 2025, to July 28, 2025, inclusive.
  • Novo Nordisk's stock price fell by 21.8% on July 29, 2025, to close at $53.94 per share.
  • The Company cited lower growth expectations for both Ozempic and Wegovy, citing a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s.

Sources:

  • GLOBE NEWSWIRE, "REINVESTOR ALERT: LAW FIRM ALERT: Brodsky & Smith, LLC Reminds Investors of a Securities Class Action Lawsuit Against Novo Nordisk A/S (NYSE: NVO) - NVO"
  • COMTEX_467988294/2010/2025-08-12T12:00:00